Dr. Williams, BriaCell Therapeutics Corp.’s President & CEO, called in to SmallcapVoice.com to go over the highlights for the Company here in the summer of 2018 and what to look from BriaCell in the fall and winter months. The company …Continue Reading→
Dr. Williams, BriaCell Therapeutics Corp.’s President & CEO, called in to SmallcapVoice.com to go over the highlights for the Company here in the summer of 2018 and what to look from BriaCell in the fall and winter months. The company recently announced the addition of the Cancer Center of Kansas (CCK) as a new clinical trial site is expected to accelerate patient enrollment in both clinical trials. As well as the hiring of Dr. Sunkari, an experienced Scientist, is intended to speed up the development of Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy.
Founded by Dr. Harry Hynes in Wichita, KS, in 1975, Cancer Center of Kansas, provides personalized, quality and innovative cancer care to patients in the mid-west. The center’s mission has been to provide the latest and highest quality diagnostic and therapeutic care to cancer patients through their commitment to excellence in medical oncology and hematology. Since 1987, CCK began extending its coverage throughout the state to serve patients in rural areas such as McPherson, Junction City, Marysville, and Neodesha. Cancer Center of Kansas currently lists 16 participating offices and 14 physicians in the State of Kansas.
With its widespread network of facilities throughout the state of Kansas, top oncologists, and excellent patient care team, CCK is aiming to provide world class cancer care to patients. Their services are focused on multiple aspects of cancer treatment including– diagnosis and treatment, blood and marrow transplants, research and clinical trials, diagnostic imaging, advanced laboratory work, and an oral medications center to better serve their patients.
Throughout the years, the CCK team has received numerous distinctions, awards and recognitions at community, national, and international levels for the the center’s excellence in patient care, and the expertise of its physicians. For the full list of awards, please see: https://cancercenterofkansas.com/awards-recognition/.
For more information on the Cancer Center of Kansas, please visit https://cancercenterofkansas.com/.
This interview may include forward looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this release. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. SmallCapVoice.com, Inc. received 2,500 from the company on 4-2-18 for 30 days of service. On 5-15-18 BCTXF Signed a 60 day agreement with a payment of $2,500.00 at the execution of the contract and additional $2,500.00 due 6-15-18.
Dr. Williams, BriaCell Therapeutics Corp.’s President & CEO, called in to SmallcapVoice.com to go over the highlights for the Company here in the summer of 2018 and what to look from BriaCell in the fall and winter months. The company recently announced the addition of the Cancer Center of Kansas (CCK) as a new clinical trial site is expected to accelerate patient enrollment in both clinical trials. As well as the hiring of Dr. Sunkari, an experienced Scientist, is intended to speed up the development of Bria-OTS™,
